Fidelis Capital Partners, LLC Repligen Corp Transaction History
Fidelis Capital Partners, LLC
- $654 Billion
- Q1 2024
A detailed history of Fidelis Capital Partners, LLC transactions in Repligen Corp stock. As of the latest transaction made, Fidelis Capital Partners, LLC holds 625 shares of RGEN stock, worth $77,381. This represents 0.06% of its overall portfolio holdings.
Number of Shares
625Holding current value
$77,381% of portfolio
0.06%Shares
1 transactions
Others Institutions Holding RGEN
# of Institutions
517Shares Held
53.3MCall Options Held
1.05MPut Options Held
228K-
Black Rock Inc. New York, NY7.77MShares$962 Million0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.1MShares$631 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.57MShares$442 Million0.08% of portfolio
-
State Street Corp Boston, MA1.76MShares$218 Million0.01% of portfolio
-
Macquarie Group LTD Australia, C31.46MShares$181 Million0.31% of portfolio
About REPLIGEN CORP
- Ticker RGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 55,491,200
- Market Cap $6.87B
- Description
- Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....